{
    "id": "348dbfd5-d64b-75f2-e063-6394a90ab0a6",
    "indications": "sumatriptan tablets indicated acute treatment migraine without aura adults . limitations : clear diagnosis migraine headache established . patient response first migraine attack treated sumatriptan tablets , reconsider diagnosis migraine sumatriptan tablets administered treat subsequent attacks . sumatriptan tablets indicated prevention migraine attacks . safety effectiveness sumatriptan tablets established cluster headache .",
    "contraindications": "single dose 25 mg , 50 mg , 100 mg tablet . ( 2.1 ) second dose considered response first dose observed . separate doses least 2 hours . ( 2.1 ) maximum dose 24-hour period : 200 mg. ( 2.1 ) maximum single dose exceed 50 mg patients mild moderate hepatic impairment . ( 2.2 )",
    "warningsAndPrecautions": "sumatriptan tablets usp , 100 mg sumatriptan ( base ) succinate . sumatriptan tablets usp , 100 mg white off-white , capsule shaped , biconvex uncoated tablets , debossed ‘ c ’ one side ‘ 34 ’ side . ndc : 70518-1184-00 packaging : 1 1 carton . 9 1 blister pack type 0 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "sumatriptan tablets contraindicated patients : ischemic coronary artery disease ( cad ) ( angina pectoris , history myocardial infarction , documented silent ischemia ) coronary artery vasospasm , including prinzmetal ’ angina [ ( 5.1 ) ] wolff-parkinson-white syndrome arrhythmias associated cardiac accessory conduction pathway disorders [ ( 5.2 ) ] history stroke transient ischemic attack ( tia ) history hemiplegic basilar migraine patients higher risk stroke [ ( 5.4 ) ] peripheral vascular disease [ ( 5.5 ) ] ischemic bowel disease [ ( 5.5 ) ] uncontrolled hypertension [ ( 5.8 ) ] recent ( i.e . , within 24 hours ) ergotamine-containing medication , ergot-type medication ( dihydroergotamine methysergide ) , another 5-hydroxytryptamine 1 ( 5-ht 1 ) agonist [ ( 7.1 , 7.3 ) ] concurrent monoamine oxidase ( mao ) -a inhibitor recent ( within 2 weeks ) mao-a inhibitor [ ( 7.2 ) , pharmacology ( 12.3 ) ] hypersensitivity sumatriptan tablets ( angioedema anaphylaxis seen ) [ ( 5.9 ) ] severe hepatic impairment [ ( 8.6 ) , pharmacology ( 12.3 ) ]",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "L11K75P92J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "SUMATRIPTAN SUCCINATE",
            "code": "J8BDZ68989"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "Sumatriptan",
    "effectiveTime": "20250507",
    "indications_original": "Sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. \n  \n                     \n                          Limitations of Use:\n  \n                  \n                  \n                     Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan tablets, reconsider the diagnosis of migraine before sumatriptan tablets are administered to treat any subsequent attacks.\n                     Sumatriptan tablets are not indicated for the prevention of migraine attacks.\n                     Safety and effectiveness of sumatriptan tablets have not been established for cluster headache.",
    "contraindications_original": "Single dose of 25 mg, 50 mg, or 100 mg tablet. ( 2.1 ) A second dose should only be considered if some response to the first dose was observed. Separate doses by at least 2 hours. ( 2.1 ) Maximum dose in a 24-hour period: 200 mg. ( 2.1 ) Maximum single dose should not exceed 50 mg in patients with mild to moderate hepatic impairment. ( 2.2 )",
    "warningsAndPrecautions_original": "Sumatriptan Tablets USP, 100 mg of sumatriptan (base) as the succinate.\n                  Sumatriptan Tablets USP, 100 mg are white to off-white, capsule shaped, biconvex uncoated tablets, debossed with ‘C’ on one side and ‘34’ on other side.\n                  NDC: 70518-1184-00\n                  PACKAGING: 1 in 1 CARTON. 9 in 1 BLISTER PACK TYPE 0\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Sumatriptan tablets are contraindicated in patients with: \n                  \n                     Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina\n  \n   [see\n   \n    Warnings and Precautions (5.1)]\n  \n   \n                     \n                     Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders\n  \n   [see\n   \n    Warnings and Precautions (5.2)]\n  \n   \n                     \n                     History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke\n  \n   [see\n  \n   \n                           Warnings and Precautions (5.4)]\n  \n   \n                     \n                     Peripheral vascular disease\n  \n   [see \n                        \n                           Warnings and Precautions (5.5)]\n  \n   \n                     \n                     Ischemic bowel disease\n  \n   [see \n                        \n                           Warnings and Precautions (5.5)]\n  \n   \n                     \n                     Uncontrolled hypertension\n  \n   [see \n                        \n                           Warnings and Precautions (5.8)]\n  \n   \n                     \n                     Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine\n  \n   1(5-HT\n  \n   1) agonist\n  \n   [see \n   \n    Drug Interactions (7.1, \n   \n    7.3)]\n  \n   \n                     \n                     Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor\n  \n   [see \n   \n    Drug Interactions (7.2),\n   \n    Clinical Pharmacology (12.3)]\n  \n   \n                     \n                     Hypersensitivity to sumatriptan tablets (angioedema and anaphylaxis seen)\n  \n   [see\n   \n    Warnings and Precautions (5.9)]\n  \n   \n                     \n                     Severe hepatic impairment\n  \n   [see\n   \n    Use in Specific Populations (8.6), \n   \n    Clinical Pharmacology (12.3)]"
}